This paper reviews the impact of genetic variability of drug metabolizing enzymes, transporters, receptors, and pathways involved in chronic pain perception on the efficacy and safety of analgesics and other drugs used for chronic pain treatment. Several candidate genes have been identified in the literature, while there is usually only limited clinical evidence substantiating for the penetration of the testing for these candidate biomarkers into the clinical practice. Further, the pain-perception regulation and modulation are still not fully understood, and thus more complex knowledge of genetic and epigenetic background for analgesia will be needed prior to the clinical use of the candidate genetic biomarkers.

1st Faculty of Medicine Institute of Pharmacology Charles University Prague Albertov 4 12800 Prague Czech Republic

Zobrazit více v PubMed

Hocking LJ, Smith BH, Jones GT, Reid DM, Strachan DP, Macfarlane GJ. Genetic variation in the beta2-adrenergic receptor but not catecholamine-O-methyltransferase predisposes to chronic pain: results from the 1958 British Birth Cohort Study. Pain. 2010;149(1):143–151. PubMed

Finan PH, Zautra AJ, Davis MC, Lemery-Chalfant K, Covault J, Tennen H. Genetic influences on the dynamics of pain and affect in fibromyalgia. Health Psychology. 2010;29(2):134–142. PubMed PMC

Fijal B, Perlis RH, Heinloth AN, Houston JP. The association of single nucleotide polymorphisms in the catechol-O-methyltransferase gene and pain scores in female patients with major depressive disorder. Journal of Pain. 2010;11(9):910–915. PubMed

Fernandez-de-las-Penas C, Ambite-Quesada S, Rivas-Martinez I, et al. Genetic contribution of catechol-O-methyltransferase polymorphism (Val158Met) in children with chronic tension-type headache. Pediatric Research. 2011;70(4):395–399. PubMed

Barbosa FR, Matsuda JB, Mazucato M, et al. Influence of catechol-O-methyltransferase (COMT) gene polymorphisms in pain sensibility of Brazilian fibromialgia patients. Rheumatology International. 2012;32(2):427–430. PubMed

Loggia ML, Jensen K, Gollub RL, Wasan AD, Edwards RR, Kong J. The catechol-O-methyltransferase (COMT) val158met polymorphism affects brain responses to repeated painful stimuli. PLoS One. 2011;6(11)e27764 PubMed PMC

Dai F, Belfer I, Schwartz CE, et al. Association of catechol-O-methyltransferase genetic variants with outcome in patients undergoing surgical treatment for lumbar degenerative disc disease. Spine Journal. 2010;10(11):949–957. PubMed

Omair A, Lie BA, Reikeras O, Holden M, Brox JI. Genetic contribution of catechol-O-methyltransferase variants in treatment outcome of low back pain: a prospective genetic association study. BMC Musculoskeletal Disorders. 2012;13, article 76 PubMed PMC

Martinez-Jauand M, Sitges C, Rodriguez V, et al. Pain sensitivity in fibromyalgia is associated with catechol-O-methyltransferase (COMT) gene. European Journal of Pain. 2013;17(1):16–27. PubMed

Klepstad P, Rakvåg TT, Kaasa S, et al. The 118 A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiologica Scandinavica. 2004;48(10):1232–1239. PubMed

Olsen MB, Jacobsen LM, Schistad EI, et al. Pain intensity the first year after lumbar disc herniation is associated with the A118G polymorphism in the opioid receptor mu 1 gene: evidence of a sex and genotype interaction. Journal of Neuroscience. 2012;32(29):9831–9834. PubMed PMC

Menon S, Lea RA, Roy B, et al. The human mu-opioid receptor gene polymorphism (A118G) is associated with head pain severity in a clinical cohort of female migraine with aura patients. Journal of Headache and Pain. 2012;13(7):513–519. PubMed PMC

Janicki PK, Schuler G, Francis D, et al. A genetic association study of the functional A118G polymorphism of the human μ-opioid receptor gene in patients with acute and chronic pain. Anesthesia and Analgesia. 2006;103(4):1011–1017. PubMed

Heddini U, Bohm-Starke N, Gronbladh A, Nyberg F, Nilsson KW, Johannesson U. GCH1-polymorphism and pain sensitivity among women with provoked vestibulodynia. Molecular Pain. 2012;8, article 68 PubMed PMC

Carreno O, Corominas R, Fernandez-Morales J, et al. SNP variants within the vanilloid TRPV1 and TRPV3 receptor genes are associated with migraine in the Spanish population. The American Journal of Medical Genetics. 2012;159(1):94–103. PubMed

Reeder JE, Byler TK, Foster DC, et al. Polymorphism in the SCN9A voltage-gated sodium channel gene associated with interstitial cystitis/bladder pain syndrome. Urology. 2013;81(1):210.e1–210.e4. PubMed

Costigan M, Belfer I, Griffin RS, et al. Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain. 2010;133(9):2519–2527. PubMed PMC

Nissenbaum J, Devor M, Seltzer Z, et al. Susceptibility to chronic pain following nerve injury is genetically affected by CACNG2. Genome Research. 2010;20(9):1180–1190. PubMed PMC

Diatchenko L, Anderson AD, Slade GD, et al. Three major haplotypes of the β2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. The American Journal of Medical Genetics. 2006;141(5):449–462. PubMed PMC

Nicholl BI, Holliday KL, MacFarlane GJ, et al. Association of HTR2A polymorphisms with chronic widespread pain and the extent of musculoskeletal pain: results from two population-based cohorts. Arthritis and Rheumatism. 2011;63(3):810–818. PubMed

Laugsand EA, Fladvad T, Skorpen F, et al. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. European Journal of Cancer. 2011;47(11):1682–1691. PubMed

Klepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain. 2011;152(5):1139–1145. PubMed

Reyes-Gibby CC, Shete S, Rakvåg T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130(1-2):25–30. PubMed PMC

Lötsch J, von Hentig N, Freynhagen R, et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and Genomics. 2009;19(6):429–436. PubMed

Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the Catechol-O-Methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Molecular Pain. 2008;4, article 64 PubMed PMC

Ross JR, Riley J, Taegetmeyer AB, et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer. 2008;112(6):1390–1403. PubMed

Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clinical Pharmacology and Therapeutics. 2008;83(4):559–566. PubMed

Liu YC, Wang WS. Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer. 2012;118(6):1718–1725. PubMed

Droney JM, Gretton SK, Sato H, et al. Analgesia and central side-effects: two separate dimensions of morphine response. British Journal of Clinical Pharmacology. 2013;75(5):1340–1350. PubMed PMC

Nishizawa D, Fukuda K, Kasai S, et al. Genome-wide association study identifies a potent locus associated with human opioid sensitivity. Molecular Psychiatry. 2012 PubMed PMC

Lötsch J, Prüss H, Veh RW, Doehring A. A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenetics and Genomics. 2010;20(5):291–297. PubMed

Ho AMC, Tang NLS, Cheung BKL, Stadlin A. Dopamine receptor D4 gene -521C/T polymorphism is associated with opioid dependence through cold-pain responses. Annals of the New York Academy of Sciences. 2008;1139:20–26. PubMed

Brasch-Andersen C, Moller MU, Christiansen L, et al. A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C) European Journal of Clinical Pharmacology. 2011;67(11):1131–1137. PubMed

Mitrovic I, Margeta-Mitrovic M, Bader S, Stoffel M, Jan LY, Basbaum AI. Contribution of GIRK2-mediated postsynaptic signaling to opiate and α2-adrenergic analgesia and analgesic sex differences. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(1):271–276. PubMed PMC

Li T, Zhu ZH, Liu X, et al. Association analysis of polymorphisms in the DRD4 gene and heroin abuse in Chinese subjects. The American Journal of Medical Genetics. 2000;96(5):616–621. PubMed

Constantin CE, Mair N, Sailer CA, et al. Endogenous tumor necrosis factor α (TNFα) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. Journal of Neuroscience. 2008;28(19):5072–5081. PubMed PMC

Reyes-Gibby CC, Spitz M, Wu X, et al. Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-α-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiology Biomarkers and Prevention. 2007;16(12):2745–2751. PubMed

Reyes-Gibby CC, El Osta B, Spitz MR, et al. The influence of tumor necrosis factor-α -308 G/A and IL-6- 174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiology Biomarkers and Prevention. 2008;17(11):3262–3267. PubMed PMC

Reyes-Gibby CC, Spitz MR, Yennurajalingam S, et al. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiology Biomarkers and Prevention. 2009;18(10):2636–2642. PubMed PMC

Shoskes DA, Albakri Q, Thomas K, Cook D. Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response. Journal of Urology. 2002;168(1):331–335. PubMed

Rausch SM, Gonzalez BD, Clark MM, et al. SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors. Lung Cancer. 2012;77(1):217–223. PubMed PMC

Solovieva S, Leino-Arjas P, Saarela J, Luoma K, Raininko R, Riihimäki H. Possible association of interleukin 1 gene locus polymorphisms with low back pain. Pain. 2004;109(1-2):8–19. PubMed

McCann B, Miaskowski C, Koetters T, et al. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. Journal of Pain. 2012;13(5):425–437. PubMed PMC

Illi J, Miaskowski C, Cooper B, et al. Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine. 2012;58(3):437–447. PubMed PMC

Oen K, Malleson PN, Cabral DA, et al. Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis. Rheumatology. 2005;44(9):1115–1121. PubMed

Reyes-Gibby CC, Shete S, Yennurajalingam S, et al. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. Journal of Pain and Symptom Management. 2009;38(6):894–902. PubMed PMC

Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology. 2011;87(5-6):274–285. PubMed

Smith MA, Marinaki AM, Sanderson JD. Pharmacogenomics in the treatment of inflammatory bowel disease. Pharmacogenomics. 2010;11(3):421–437. PubMed

Aithal GP, Day CP, Leathart JBS, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics. 2000;10(6):511–518. PubMed

Tracy TS, Matthew Hutzler J, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metabolism and Disposition. 2002;30(4):385–390. PubMed

Wyatt JE, Pettit WL, Harirforoosh S. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. Pharmacogenomics Journal. 2012;12(6):462–467. PubMed

Hirota T, Eguchi S, Ieiri I. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metabolism and Pharmacokinetics. 2013;28(1):28–37. PubMed

García-Martín E, Martínez C, Tabarés B, Frías J, Agúndez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clinical Pharmacology and Therapeutics. 2004;76(2):119–127. PubMed

Durrmeyer X, Hovhannisyan S, Médard Y, et al. Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants? PLoS One. 2010;23(5)12329 PubMed PMC

Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132(1):272–281. PubMed

Smith MT, Muralidharan A. Pharmacogenetics of pain and analgesia. Clinical Genetics. 2012;82(4):321–330. PubMed

Chen C, Wang SC, Tsou HH, et al. Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics. 2011;1210(10):1397–1406. PubMed

Yuan R, Zhang X, Deng Q, Wu Y, Xiang G. Impact of CYP3A4 1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clinica Chimica Acta. 2011;412(9-10):755–760. PubMed

Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics Journal. 2012;13(1):1–11. PubMed

Shiotani A, Sakakibara T, Nomura M, et al. Aspirin-induced peptic ulcer and genetic polymorphisms. Journal of Gastroenterology and Hepatology. 2010;25(supplement 1):S31–S34. PubMed

Fujita KI, Ando Y, Yamamoto W, et al. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemotherapy and Pharmacology. 2010;65(2):251–258. PubMed

Holthe M, Klepstad P, Zahlsen K, et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. European Journal of Clinical Pharmacology. 2002;58(5):353–356. PubMed

Joly P, Gagnieu MC, Bardel C, Francina A, Pondarre C, Martin C. Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. The American Journal of Hematology. 2012;87(5):534–536. PubMed

Sánchez MB, Herranz JL, Leno C, et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure. 2010;19(2):93–101. PubMed

Hung CC, Ho JL, Chang WL, et al. Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics. 2011;12(8):1107–1117. PubMed

Mimura Y, Maruo Y, Ohta Y, Sato H, Takeuchi Y. Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family. Basic and Clinical Pharmacology and Toxicology. 2011;109(6):486–493. PubMed

Fortuny J, Kogevinas M, Garcia-Closas M, et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiology Biomarkers and Prevention. 2006;15(9):1696–1702. PubMed

Bond C, Laforge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(16):9608–9613. PubMed PMC

Zhang Y, Wang D, Johnson AD, Papp AC, Sadée W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. Journal of Biological Chemistry. 2005;280(38):32618–32624. PubMed

Oertel BG, Kettner M, Scholich K, et al. A common human μ-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. Journal of Biological Chemistry. 2009;284(10):6530–6535. PubMed

Lopez Soto EJ, Raingo J. A118G Mu Opioid Receptor polymorphism increases inhibitory effects on CaV2. 2 channels. Neuroscience Letters. 2012;523(2):190–194. PubMed

Walter C, Lötsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain. 2009;146(3):270–275. PubMed

Anzenbacher P, Zanger UM, editors. Metabolism of Drugs and Other Xenobiotics. 1 edition. Weinheim, Germany: Wiley-VCH; 2012.

Food. Pharmacogenomic biomarkers in drug labels. 2012, http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.

PharmGKB. Drug labels. 2012, http://www.pharmgkb.org/search/labelList.action.

Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology and Therapeutics. 2006;80(6):682–690. PubMed

Levran O, O’Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Human Molecular Genetics. 2008;17(14):2219–2227. PubMed PMC

Barratt DT, Coller JK, Hallinan R, et al. ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Journal of Pharmacogenomics and Personalized Medicine. 2012;5:53–62. PubMed PMC

Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Human Molecular Genetics. 2005;14(1):135–143. PubMed

Hung CC, Chiou MH, Huang BH, et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011;12(11):1525–1533. PubMed

Meineke I, Freudenthaler S, Hofmann U, et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. British Journal of Clinical Pharmacology. 2002;54(6):592–603. PubMed

Coulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clinical Pharmacology and Therapeutics. 2006;79(4):316–324. PubMed

Mamie C, Rebsamen MC, Morris MA, Morabia A. First evidence of a polygenic susceptibility to pain in a pediatric cohort. Anesthesia and Analgesia. 2013;116(1):170–177. PubMed

Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clinical Pharmacology and Therapeutics. 2007;81(4):539–546. PubMed

Slanar O, Nobilis M, Kvetina J, Matouskova O, Idle JR, Perlik F. Pharmacokinetics of tramadol is affected by MDR1 polymorphism C3435T. European Journal of Clinical Pharmacology. 2007;63(4):419–421. PubMed

Zwisler ST, Enggaard TP, Noehr-Jensen L, et al. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundamental and Clinical Pharmacology. 2010;24(4):517–524. PubMed

Lovric M, Bozina N, Hajnsek S, et al. Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. Therapeutic Drug Monitoring. 2012;34(5):518–525. PubMed

Kang HA, Cho HY, Lee YB. The effect of MDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects. Archives of Pharmacal Research. 2007;30(1):96–101. PubMed

Puranik YG, Birnbaum AK, Marino SE, et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013;14(1):35–45. PubMed PMC

Sterjev Z, Trencevska GK, Cvetkovska E, et al. The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy. Neuropsychiatric Disease and Treatment. 2012;8:191–196. PubMed PMC

Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy and Behavior. 2011;21(1):27–30. PubMed

Karlsson L, Hiemke C, Carlsson B, et al. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology. 2011;215(2):367–377. PubMed

Karlsson L, Schmitt U, Josefsson M, et al. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. European Neuropsychopharmacology. 2010;20(9):632–640. PubMed

Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption. Biological Psychiatry. 2003;54(8):840–846. PubMed

Rosenhagen MC, Uhr M. Single nucleotide polymorphism in the drug transporter Gene ABCB1 in treatment-resistant depression clinical practice. Journal of Clinical Psychopharmacology. 2010;30(2):209–211. PubMed

Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. Journal of Psychiatric Research. 2003;37(3):179–185. PubMed

Uhr M, Grauer MT, Yassouridis A, Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. Journal of Psychiatric Research. 2007;41(1-2):179–188. PubMed

Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 2000;22(4):380–387. PubMed

Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Molecular Pharmacology. 2010;77(4):687–694. PubMed

Sloan JA, de Andrade M, Decker P, et al. Geneic variations and patient-reported quality of life among patients with lung cancer. ” Journal of Clinical Oncology. 2012;30(14):1699–1704. PubMed PMC

Zelcer N, van de Wetering K, Hillebrand M, et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(20):7274–7279. PubMed PMC

Lin ZP, Zhu YL, Johnson DR, et al. Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response. Molecular Pharmacology. 2008;73(1):243–251. PubMed PMC

Kosek E, Jensen KB, Lonsdorf TB, Schalling M, Ingvar M. Genetic variation in the serotonin transporter gene (5-HTTLPR, rs25531) influences the analgesic response to the short acting opioid Remifentanil in humans. Molecular Pain. 2009;5, article 37 PubMed PMC

Lindstedt F, Berrebi J, Greayer E, et al. Conditioned pain modulation is associated with common Polymorphisms in the serotonin transporter gene. PLoS ONE. 2011;6(3)e18252 PubMed PMC

Lindstedt F, Lonsdorf TB, Schalling M, Kosek E, Ingvar M. Perception of thermal pain and the thermal grill illusion is associated with polymorphisms in the serotonin transporter gene. PLoS ONE. 2011;6(3)e17752 PubMed PMC

Herken H, Erdal E, Mutlu N, et al. Possible association of temporomandibular joint pain and dysfunction with a polymorphism in the serotonin transporter gene. The American Journal of Orthodontics and Dentofacial Orthopedics. 2001;120(3):308–313. PubMed

Potvin S, Larouche A, Normand E, et al. No relationship between the ins del polymorphism of the serotonin transporter promoter and pain perception in fibromyalgia patients and healthy controls. European Journal of Pain. 2010;14(7):742–746. PubMed

Schürks M, Rist PM, Kurth T. STin2 VNTR polymorphism in the serotonin transporter gene and migraine: pooled and meta-analyses. The Journal of Headache and Pain. 2010;11(4):317–326. PubMed PMC

Kumar S, Ranjan P, Mittal B, Ghoshal UC. Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. Journal of Gastrointestinal and Liver Diseases. 2012;21(1):31–38. PubMed

Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis and Rheumatism. 1999;42(11):2482–2488. PubMed

Cevoli S, Mochi M, Scapoli C, et al. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. European Journal of Neurology. 2006;13(9):1009–1013. PubMed

Shin HE, Han SJ, Lee KS, Park JW. Polymorphism of the glutamate transporter protein EAAT2 and migraine transformation into chronic daily headache. Journal of Clinical Neurology. 2011;7(3):143–147. PubMed PMC

Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mrna, protein, and enzyme activity in postmortem human brain. The American Journal of Human Genetics. 2004;75(5):807–821. PubMed PMC

Chen JF, Aloyo VJ, Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreased D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience. 1993;54(3):669–680. PubMed

Steiner H, Gerfen CR. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Experimental Brain Research. 1998;123(1-2):60–76. PubMed

Tammimaki A, Mannisto PT. Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis. Pharmacogenet Genomics. 2012;22(9):673–691. PubMed

Diatchenko L, Nackley AG, Slade GD, et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain. 2006;125(3):216–224. PubMed

Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both β2- and β3-adrenergic receptors. Pain. 2007;128(3):199–208. PubMed PMC

McLean SA, Diatchenko L, Lee YM, et al. Catechol O-methyltransferase haplotype predicts immediate musculoskeletal neck pain and psychological symptoms after motor vehicle collision. Journal of Pain. 2011;12(1):101–107. PubMed PMC

Nicholl BI, Holliday KL, Macfarlane GJ, et al. No evidence for a role of the catechol-O-methyltransferase pain sensitivity haplotypes in chronic widespread pain. Annals of the Rheumatic Diseases. 2010;69(11):2009–2012. PubMed

Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 1998;21(3):531–543. PubMed

Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: the challenges for therapeutic targeting. Trends in Molecular Medicine. 2009;15(1):14–22. PubMed

Junger H, Sorkin LS. Nociceptive and inflammatory effects of subcutaneous TNFα . Pain. 2000;85(1-2):145–151. PubMed

Ramonda R, Lorenzin M, Modesti V, et al. Serological markers of erosive hand osteoarthritis. European Journal of Internal Medicine. 2013;24(1):11–15. PubMed

Miyashita M, Ito T, Sakaki M, et al. Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. Journal of Viral Hepatitis. 2012;19(9):608–614. PubMed

Loo WT, Bai LJ, Fan CB, et al. Clinical application of human beta-defensin and CD14 gene polymorphism in evaluating the status of chronic inflammation. Journal of Translational Medicine. 2012;10(Supplement 1):p. S9. PubMed PMC

Guzman-Ornelas MO, Chavarria-Avila E, Munoz-Valle JF, et al. Association of ADIPOQ +45T > G polymorphism with body fat mass and blood levels of soluble adiponectin and inflammation markers in a Mexican-Mestizo population. Diabetes, Metabolic Syndrome and Obesity. 2012;5:369–378. PubMed PMC

Vikram NK, Bhatt SP, Bhushan B, et al. Associations of -308G/A polymorphism of tumor necrosis factor (TNF)-alpha gene and serum TNF-alpha levels with measures of obesity, intra-abdominal and subcutaneous abdominal fat, subclinical inflammation and insulin resistance in Asian Indians in north India. Disease Markers. 2011;31(1):39–46. PubMed PMC

Sen A, Paine SK, Chowdhury IH, et al. Impact of interleukin-6 promoter polymorphism and serum interleukin-6 level on the acute inflammation and neovascularization stages of patients with Eales' disease. Molecular Vision. 2011;17:2552–2563. PubMed PMC

Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of cytokine-induced hyperalgesia. Brain Research. 1994;654(1):15–26. PubMed

Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Letters. 2003;191(2):125–135. PubMed

Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nature Reviews Cancer. 2002;2(3):201–209. PubMed

Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1 β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001;410(6827):471–475. PubMed

Hildeman D, Muller D. Immunopathologic weight loss in intracranial LCMV infection initiated by the anorexigenic effects of IL-1β . Viral Immunology. 2000;13(3):273–285. PubMed

Choi SS, Han KJ, Lee JK, et al. Antinociceptive mechanisms of orally administered decursinol in the mouse. Life Sciences. 2003;73(4):471–485. PubMed

Reeve AJ, Patel S, Fox A, Walker K, Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. European Journal of Pain. 2000;4(3):247–257. PubMed

McDowell TL, Symons JA, Ploski R, Førre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1α polymorphism. Arthritis and Rheumatism. 1995;38(2):221–228. PubMed

Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. European Journal of Clinical Investigation. 1992;22(6):396–402. PubMed

Tarlow JK, Blakemore AIF, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Human Genetics. 1993;91(4):403–404. PubMed

Voehringer D, Shinkai K, Locksley RM. Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity. 2004;20(3):267–277. PubMed

de Waal Malefyt R, Figdor CG, Huijbens R, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes: comparison with IL-4 and modulation by IFN-γ or IL-10. Journal of Immunology. 1993;151(11):6370–6381. PubMed

Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(8):3730–3734. PubMed PMC

Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. Journal of Clinical Investigation. 1998;101(2):311–320. PubMed PMC

Matsushima K, Morishita K, Yoshimura T, et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. Journal of Experimental Medicine. 1988;167(6):1883–1893. PubMed PMC

Seitz M, Dewald B, Gerber N, Baggiolini M. Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. Journal of Clinical Investigation. 1991;87(2):463–469. PubMed PMC

Jannetto PJ, Bratanow NC. Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring. Expert Opinion on Drug Metabolism and Toxicology. 2011;7(6):745–752. PubMed

Smith SB, Maixner DW, Fillingim RB, et al. Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia. Arthritis and Rheumatism. 2012;64(2):584–593. PubMed PMC

Allegri M, de gregori M, Niebel T, et al. Pharmacogenetics and postoperative pain: a new approach to improve acute pain management. Minerva Anestesiologica. 2010;76(11):937–944. PubMed

Buzkova H, Pechandova K, Slanar O, Perlik F. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochemistry and Function. 2008;26(1):76–81. PubMed

Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenetics and Genomics. 2007;17(2):93–101. PubMed

Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF, Elbæk K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. European Journal of Clinical Pharmacology. 1996;51(3-4):289–295. PubMed

Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. The Lancet. 2006;368(9536):p. 704. PubMed

Landau R, Bollag LA, Kraft JC. Pharmacogenetics and anaesthesia: the value of genetic profiling. Anaesthesia. 2012;67(2):165–179. PubMed

Food. Information for healthcare professionals: use of codeine products in nursing mothers. 2007.

European Medicines Agency. Review of codeine-containing medicines started. 2012.

Sadhasivam S, Myer CM. Preventing opioid-related deaths in children undergoing surgery. Pain Medicine. 2012;12(7):982–983. PubMed

Garrido MJ, Valle M, Campanero MA, Calvo R, Trocóniz IF. Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats. Journal of Pharmacology and Experimental Therapeutics. 2000;295(1):352–359. PubMed

Slanar O, Dupal P, Matouskova O, Vondrackova H, Pafko P, Perlik F. Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. Bratislava Medical Journal. 2012;113(3):152–155. PubMed

Fleeman N, Martin Saborido C, Payne K, et al. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technology Assessment. 2011;15(33):1–102. PubMed PMC

Blanco G, Martínez C, Ladero JM, et al. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenetics and Genomics. 2008;18(1):37–43. PubMed

Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML. Is cytochrome p450 2c9 genotype associated with NSAID gastric ulceration? British Journal of Clinical Pharmacology. 2001;51(6):627–630. PubMed PMC

Agúndez JAG, García-Martín E, Martínez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opinion on Drug Metabolism and Toxicology. 2009;5(6):607–620. PubMed

Mrazek DA, Biernacka JM, O’Kane DJ, et al. CYP2C19 variation and citalopram response. Pharmacogenetics and Genomics. 2011;21(1):1–9. PubMed PMC

Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry. 2004;9(5):442–473. PubMed

McAlpine DE, Biernacka JM, Mrazek DA, et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Therapeutic Drug Monitoring. 2011;33(1):14–20. PubMed

Martínez C, García-Martín E, Blanco G, Gamito FJG, Ladero JM, Agúndez JAG. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. British Journal of Clinical Pharmacology. 2005;59(1):62–68. PubMed PMC

Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. European Journal of Clinical Pharmacology. 2001;57(10):729–735. PubMed

Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clinical Pharmacology and Therapeutics. 2004;76(1):18–26. PubMed

Wang Y, Zhou D, Wang B, et al. A kindling model of pharmacoresistant temporal lobe epilepsy in Sprague-Dawley rats induced by Coriaria lactone and its possible mechanism. Epilepsia. 2003;44(4):475–488. PubMed

Jin M, Gock SB, Jannetto PJ, Jentzen JM, Wong SH. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. Journal of Analytical Toxicology. 2005;29(7):590–598. PubMed

Wong SH, Wagner MA, Jentzen JM, et al. Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity? Journal of Forensic Sciences. 2003;48(6):1406–1415. PubMed

Jannetto PJ, Wong SH, Gock SB, Laleli-Sahin E, Schur BC, Jentzen JM. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. Journal of Analytical Toxicology. 2002;26(7):438–447. PubMed

Hakooz N, Alzubiedi S, Yousef AM, et al. UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population. Molecular Biology Reports. 2012;39(7):7763–7768. PubMed

Sawyer MB, Innocenti F, Das S, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clinical Pharmacology and Therapeutics. 2003;73(6):566–574. PubMed

Chen Y, Kuehl GE, Bigler J, et al. UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. Pharmacogenetics and Genomics. 2007;17(8):571–579. PubMed

Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell. 1994;77(7):1071–1081. PubMed

van Helvoort A, Smith AJ, Sprong H, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 1996;87(3):507–517. PubMed

Yamaguchi H, Hishinuma T, Endo N, et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. International Journal of Gynecological Cancer. 2006;16(3):979–985. PubMed

Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenetics and Genomics. 2005;15(11):779–786. PubMed

Callaghan R, Riordan JR. Synthetic and natural opiates interact with P-glycoprotein in multidrug- resistant cells. Journal of Biological Chemistry. 1993;268(21):16059–16064. PubMed

Bouer R, Barthe L, Philibert C, Tournaire C, Woodley J, Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundamental and Clinical Pharmacology. 1999;13(4):494–500. PubMed

Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology and Therapeutics. 2000;68(3):231–237. PubMed

Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P- glycoprotein. Anesthesiology. 2000;92(5):1392–1399. PubMed

Rodriguez M, Ortega I, Soengas I, Suarez E, Lukas JC, Calvo R. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. Journal of Pharmacy and Pharmacology. 2004;56(3):367–374. PubMed

Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology. 2004;173(1):132–138. PubMed

Nanovskaya T, Nekhayeva I, Karunaratne N, Audus K, Hankins GDV, Ahmed MS. Role of P-glycoprotein in transplacental transfer of methadone. Biochemical Pharmacology. 2005;69(12):1869–1878. PubMed PMC

You G, Morris ME. Drug Transporters : Molecular Characterization and Role in Drug Disposition. Hoboken, NJ, USA: Wiley-Interscience; 2007.

Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy of Sciences of the United States of America. 1987;84(21):7735–7738. PubMed PMC

Beaulieu E, Demeule M, Ghitescu L, Beliveau R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochemical Journal. 1997;326(2):539–544. PubMed PMC

Melaine N, Liénard MO, Dorval I, Le Goascogne C, Lejeune H, Jégou B. Multidrug resistance genes and P-glycoprotein in the testis of the rat, mouse, guinea pig, and human. Biology of Reproduction. 2002;67(6):1699–1707. PubMed

Edwards JE, Alcorn J, Savolainen J, Anderson BD, McNamara PJ. Role of P-glycoprotein in distribution of nelfinavir across the blood-mammary tissue barrier and blood-brain barrier. Antimicrobial Agents and Chemotherapy. 2005;49(4):1626–1628. PubMed PMC

Saito T, Zhang ZJ, Tsuzuki H, et al. Expression of P-glycoprotein in inner ear capillary endothelial cells of the guinea pig with special reference to blood-inner ear barrier. Brain Research. 1997;767(2):388–392. PubMed

Gil S, Saura R, Forestier F, Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta. 2005;26(2-3):268–270. PubMed

Kalabis GM, Kostaki A, Andrews MH, Petropoulos S, Gibb W, Matthews SG. Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection. Biology of Reproduction. 2005;73(4):591–597. PubMed

Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haemotological malignancies. Hematology. 2004;9(2):91–105. PubMed

Gollapudi S, Gupta S. Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. Journal of Clinical Immunology. 2001;21(6):420–430. PubMed

Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Kurzawski M, Gawronska-Szklarz B. Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. European Journal of Pharmacology. 2005;528(1–3):27–36. PubMed

Alberto Riva UOF. CHIP Bioinformatics Tools. 2012, http://snpper.chip.org/

Luna-Tortós C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008;55(8):1364–1375. PubMed

Potschka H, Fedrowitz M, Löscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neuroscience Letters. 2002;327(3):173–176. PubMed

Luna-Tortos C, Rambeck B, Jurgens UH, Loscher W. The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharmaceutical Research. 2009;26(11):2464–2470. PubMed

Rivers F, O’Brien TJ, Callaghan R. Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations. European Journal of Pharmacology. 2008;598(1–3):1–8. PubMed

Crowe A, Teoh YK. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. Journal of Drug Targeting. 2006;14(5):291–300. PubMed

Baltes S, Fedrowitz M, Tortós CL, Potschka H, Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. Journal of Pharmacology and Experimental Therapeutics. 2007;320(1):331–343. PubMed

Ufer M, Mosyagin I, Muhle H, et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenetics and Genomics. 2009;19(5):353–362. PubMed

Brandt C, Bethmann K, Gastens AM, Löscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiology of Disease. 2006;24(1):202–211. PubMed

Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Annals of Pharmacotherapy. 2004;38(10):1631–1634. PubMed

Kim DW, Kim M, Lee SK, Kang R, Lee SY. Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure. 2006;15(5):344–347. PubMed

Turgut G, Kurt E, Sengul C, et al. Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Molecular Biology Reports. 2009;36(3):495–499. PubMed

Hung CC, Chang WL, Ho JL, et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012;13(2):159–169. PubMed

Ozgon GO, Bebek N, Gul G, Cine N. Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. European Neurology. 2007;59(1-2):67–70. PubMed

Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(15):5507–5512. PubMed PMC

Bundgaard C, Jensen CJ, Garmer M. Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice. Drug Metabolism and Disposition. 2012;40(3):461–466. PubMed

'Brien FEO, Clarke G, Fitzgerald P, Dinan TG, Griffin BT, Cryan JF. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. British Journal of Pharmacology. 2012;166(4):1333–1343. PubMed PMC

Abaut AY, Chevanne F, Le Corre P. Influence of efflux transporters on liver, bile and brain disposition of amitriptyline in mice. International Journal of Pharmaceutics. 2009;378(1-2):80–85. PubMed

Gareri P, De Fazio P, Gallelli L, et al. Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. Annals of Pharmacotherapy. 2008;42(3):434–438. PubMed

Abaut AY, Chevanne F, Le Corre P. Oral bioavailability and intestinal secretion of amitriptyline: role of P-glycoprotein? International Journal of Pharmaceutics. 2007;330(1-2):121–128. PubMed

Ejsing TB, Hasselstrøm J, Linnet K. The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabolism and Drug Interactions. 2006;21(3-4):139–162. PubMed

Ejsing TB, Linnet K. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier. Human Psychopharmacology. 2005;20(2):149–153. PubMed

Wikinski S. Pharmacokinetic mechanisms underlying resistance in psychopharmacological treatment. The role of P-glycoprotein. Vertex. 2005;16(64):438–441. PubMed

Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annual Review of Genomics and Human Genetics. 2005;6:123–142. PubMed

Akanuma SI, Hosoya KI, Ito S, Tachikawa M, Terasaki T, Ohtsuki S. Involvement of multidrug resistance-associated protein 4 in efflux transport of prostaglandin E2 across mouse blood-brain barrier and its inhibition by intravenous administration of cephalosporins. Journal of Pharmacology and Experimental Therapeutics. 2010;333(3):912–919. PubMed

Rius M, Thon WF, Keppler D, Nies AT. Prostanoid transport by multidrug resistance protein 4 (MRP4/ABCC4) localized in tissues of the human urogenital tract. Journal of Urology. 2005;174(6):2409–2414. PubMed

Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti inflammatory drugs. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(16):9244–9249. PubMed PMC

Eikelboom JW, Hankey GJ. Overexpression of the multidrug resistance protein-4 transporter in patients undergoing coronary artery bypass graft surgery: a cause of aspirin resistance? Journal of the American College of Cardiology. 2011;58(7):762–764. PubMed

Mattiello T, Guerriero R, Lotti LV, et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-Mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. Journal of the American College of Cardiology. 2011;58(7):752–761. PubMed

Jensen LE, Wall AM, Cook M, et al. A common ABCC2 promoter polymorphism is not a determinant of the risk of spina bifida. Birth Defects Research Part A. 2004;70(6):396–399. PubMed

Haenisch S, Zimmermann U, Dazert E, et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics Journal. 2007;7(1):56–65. PubMed

Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 2001;11(2):175–184. PubMed

Hirouchi M, Suzuki H, Itoda M, et al. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharmaceutical Research. 2004;21(5):742–748. PubMed

Ufer M, von Stulpnagel C, Muhle H, et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics. 2011;21(10):624–630. PubMed

Eraly SA, Bush KT, Sampogna RV, Bhatnagar V, Nigam SK. The molecular pharmacology of organic anion transporters: from DNA to FDA? Molecular Pharmacology. 2004;65(3):479–487. PubMed

Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier-Abt PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics. 2000;294(1):73–79. PubMed

Michalski C, Cui Y, Nies AT, et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. Journal of Biological Chemistry. 2002;277(45):43058–43063. PubMed

Aoki J, Ikeda K, Murayama O, Yoshihara E, Ogai Y, Iwahashi K. The association between personality, pain threshold and a single nucleotide polymorphism (rs3813034) in the 3′-untranslated region of the serotonin transporter gene (SLC6A4) Journal of Clinical Neuroscience. 2010;17(5):574–578. PubMed

Schürks M, Rist PM, Kurth T. 5-HTTLPR polymorphism in the serotonin transporter gene and migraine: a systematic review and meta-analysis. Cephalalgia. 2010;30(11):1296–1305. PubMed PMC

Gursoy S. Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. Clinical Rheumatology. 2002;21(3):194–197. PubMed